Astellas Pharma (OTCMKTS:ALPMY) Sees Unusually-High Trading Volume – Should You Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw strong trading volume on Tuesday . 112,791 shares traded hands during trading, a decline of 33% from the previous session’s volume of 168,276 shares.The stock last traded at $13.58 and had previously closed at $13.25.

Wall Street Analysts Forecast Growth

ALPMY has been the subject of a number of research reports. Zacks Research upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 23rd. Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Astellas Pharma Price Performance

The company has a debt-to-equity ratio of 0.17, a current ratio of 1.17 and a quick ratio of 0.90. The stock has a fifty day simple moving average of $13.61 and a 200-day simple moving average of $14.64. The company has a market capitalization of $24.58 billion, a price-to-earnings ratio of 12.65 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Monday, April 27th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 23.54%. The business had revenue of $3.38 billion for the quarter, compared to analysts’ expectations of $3.28 billion. On average, equities research analysts anticipate that Astellas Pharma Inc. will post 1.25 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).